Recent advances in the treatment of Kawasaki disease

Journal of the Chinese Medical Association

Volumn 74, Issue 11, 2011, Pages 481-484

  Weng, Ken Pen ^a,b   Ou, Shan F ^c   Lin, Chu Chuan ^a   Hsieh, Kai Sheng ^a  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b SHU ZEN JUNIOR COLLEGE OF MEDICINE AND MANAGEMENT   (Taiwan)

^c ZUOYING ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

Coronary artery lesions; Intravenous immunoglobulin; Kawasaki disease

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPYRIDAMOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; WARFARIN;

ATHEROSCLEROSIS; CHRONIC INFLAMMATION; CORONARY ARTERY DISEASE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENDOTHELIAL DYSFUNCTION; GOLD STANDARD; GROUPS BY AGE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LIVER TOXICITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PLASMAPHERESIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ASPIRIN; CORONARY ARTERY DISEASE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME;

EID: 81455158365     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2011.09.001     Document Type: Review

References (46)

1. Newburger J.W., Takahashi M., Gerber M.A., Gewitz M.H., Tani L.Y., Burns J.C., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young, American heart association. Circulation 2004, 110:2747-2771.
2. Kato H., Ichinose E., Yoshioka F., Takechi T., Matsunaga S., Suzuki K., et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982, 49:1758-1766.
3. Kato H., Ichinose E., Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986, 108:923-927.
4. Suzuki A., Kamiya T., Kuwahara N., Ono Y., Kohata T., Takahashi O., et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986, 7:3-9.
5. Senzaki H. Long-term outcome of Kawasaki disease. Circulation 2008, 118:2763-2772.
6. Hsieh K.S., Weng K.P., Lin C.C., Huang T.C., Lee C.L., Huang S.M. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004, 114:e689-e693.
7. Huang W.C., Huang L.M., Chang I.S., Chang L.Y., Chiang B.L., Chen P.J., et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 2009, 123:e401-e405. and the Kawasaki Disease Research Group.
8. Nakamura Y., Yashiro M., Uehara R., Sadakane A., Chihara I., Aoyama Y., et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010, 20:302-307.
9. Park Y.W., Han J.W., Hong Y.M., Ma J.S., Cha S.H., Kwon T.C., et al. Epidemiological features of Kawasaki disease in Korea, 2006-2008. Pediatr Int 2011, 53:36-39.
10. Juan C.C., Hwang B., Lee P.C., Lin Y.J., Chien J.C., Lee H.Y., et al. The clinical manifestations and risk factors of a delayed diagnosis of Kawasaki disease. J Chin Med Assoc 2007, 70:374-379.
11. Newburger J.W., Takahashi M., Beiser A.S., Burns J.C., Bastian J., Chung K.J., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633-1639.
12. Shulman S.T. IVGG therapy in Kawasaki disease: mechanism(s) of action. Clin Immunol Immunopathol 1989, 53:S141-S146.
13. Takatsuki S., Ito Y., Takeuchi D., Hoshida H., Nakayama T., Matsuura H., et al. IVIG reduced vascular oxidative stress in patients with Kawasaki disease. Circ J 2009, 73:1315-1318.
14. Lau A.C., Duong T.T., Ito S., Yeung R.S. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009, 60:2131-2141.
15. Sundel R.P., Burns J.C., Baker A., Beiser A.S., Newburger J.W. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993, 123:657-659.
16. Burns J.C., Capparelli E.V., Brown J.A., Newburger J.W., Glode M.P. Intravenous gamma-globulin treatment and re-treatment in Kawasaki disease. Pediatr Infect Dis J 1998, 17:1144-1148.
17. Fukunishi M., Kikkawa M., Hamana K., Onodera T., Matsuzaki K., Matsumoto Y., et al. Prediction of non-responsiveness to intravenous high-dose c-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000, 137:172-176.
18. Durongpisitkul K., Soongswang J., Laohaprasitiporn D., Nana A., Prachuabmoh C., Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003, 24:145-148.
19. Sano T., Kurotobi S., Matsuzaki K., Yamamoto T., Maki I., Miki K., et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007, 166:131-137.
20. Tremoulet A.H., Best B.M., Song S., Wang S., Corinaldesi E., Eichenfield J.R., et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008, 153:117-121.
21. Shulman S.T. Is there a role for corticosteroids in Kawasaki disease?. J Pediatr 2003, 142:601-603.
22. Oishi T., Fujieda M., Shiraishi T., Ono M., Inoue K., Takahashi A., et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm: a 1-month-old girl. Circ J 2008, 72:850-852.
23. Hashino K., Ishii M., Iemura M., Akagi T., Kato H. Retreatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int 2001, 43:211-217.
24. Okada K., Hara J., Maki I., Miki K., Matsuzaki K., Matsuoka T., et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr 2009, 168:181-185.
25. Shirley D.A., Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylprednisolone in a patient with a contraindication to intravenous immune globulin. Pediatr Infect Dis J 2010, 29:978-979.
26. Dajani A.S., Taubert K.A., Gerber M.A., Shulman S.T., Ferrieri P., Freed M., et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776-1780.
27. Kusakawa S., Tatara K. Efficacies and risks of aspirin in the treatment of the Kawasaki disease. Prog Clin Biol Res 1987, 250:401-413.
28. Furusho K., Kamiya T., Nakano H., Kiyosawa N., Shinomiya K., Hayashidera T., et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984, 2:1055-1058.
29. Kato H., Koike S., Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979, 63:175-179.
30. Okada Y., Shinohara M., Kobayashi T., Inoue Y., Tomomasa T., Kobayashi T., et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003, 143:363-367.
31. Newburger J.W., Sleeper L.A., McCrindle B.W., Minich L.L., Gersony W., Vetter V.L., et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007, 356:663-675.
32. Song M.S., Lee S.B., Sohn S., Oh J.H., Yoon K.L., Han J.W., et al. Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J 2010, 40:334-338.
33. Son M.B., Gauvreau K., Burns J.C., Corinaldesi E., Tremoulet A.H., Watson V.E., et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr 2011, 158:644-649.
34. Weng K.P., Hsieh K.S., Ho T.Y., Huang S.H., Lai C.R., Chiu Y.T., et al. IL-1B polymorphism in association with initial intravenous immunoglobulin treatment failure in Taiwanese children with Kawasaki disease. Circ J 2010, 74:544-551.
35. Abbate A., Salloum F.N., Vecile E., Das A., Hoke N.N., Straino S., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 2008, 117:2670-2683.
36. Wallace C.A., French J.W., Kahn S.J., Sherry D.D. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000, 105:E78.
37. Lee T.J., Kim K.H., Chun J.K., Kim D.S. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008, 49:714-718.
38. Mori M., Imagawa T., Katakura S., Miyamae T., Okuyama K., Ito S., et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004, 14:43-47.
39. Mitani Y., Sawada H., Hayakawa H., Aoki K., Ohashi H., Matsumura M., et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005, 111:38-43.
40. McCrindle B.W., Mcintyre S., Kim C., Lin T., Adeli K. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis?. J Pediatr 2007, 151:244-248.
41. Pozza R.D., Bechtold S., Urschel S., Kozlik-Feldmann R., Netz H. Subclinical atherosclerosis, but normal autonomic function after Kawasaki disease. J Pediatr 2007, 151:239-243.
42. Massy Z.A., Keane W.F., Kasiske B.L. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?. Lancet 1996, 347:102-103.
43. Wierzbicki A.S., Poston R., Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003, 99:95-112.
44. Rikitake Y., Liao J.K. Rho GTPases, statins, and nitric oxide. Circ Res 2005, 97:1232-1235.
45. Huang S.M., Weng K.P., Chang J.S., Lee W.Y., Huang S.H., Hsieh K.S. Effects of statin therapy in children complicated with coronary arterial abnormality late after Kawasaki disease. Circ J 2008, 72:1583-1587.
46. Blankier S., McCrindle B.W., Ito S., Yeung R.S. The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease. Clin Exp Immunol 2011, 164:193-201.